21世纪经济报道记者杨梦雪 上海每4起科创融资中，就有1起发生在张江。 《2025年张江企业融资榜单》显示，2025年，张江共有210家科创企业完成融资，全年发生237起融资事 件，披露融资金额278亿元，融资事件数同比增长30%，披露融资金额同比增长18%。 从行业投向来看，2025年，张江科创融资的行业投向更趋集中，生物医药、人工智能及集成电路三大先 导产业的融资合计占比达到91%，较2024年的82%进一步提升。 其中，生物医药领域依然是张江最活跃、最具全球竞争力的融资赛道。2025年，张江生物医药产业共发 生融资事件85起，占比36%，持续位居各行业首位。 此外，2025年张江人工智能产业共发生融资事件69起，占比29%，推动人工智能由"能力构建"加快迈 向"生产力释放"；集成电路产业共发生融资事件61起，占比26%，资本持续向核心技术和关键环节集 聚。 张江科创融资的规模与活跃度双双实现两位数增长，勾勒出一条逆势上扬的"修复曲线"。然而，数据跃 升的背后，一个更深层次的转变正在发生：驱动融资活力的金融力量，已悄然重塑自身的角色与逻辑。 比如，银行不再仅仅是幕后的资金提供方，而是以"全生命周期合伙人" ...

Core Viewpoint - Junshi Biosciences has established a new subsidiary in Shanghai with a registered capital of 500 million yuan, indicating its ongoing expansion and investment in biotechnology [1] Group 1 - The newly established subsidiary is named Shanghai Junyile Biotechnology Co., Ltd. [1] - The registered capital of the new company is 500 million yuan [1] - The business scope of the subsidiary includes technology services, development, consulting, exchange, transfer, promotion, import and export of goods and technology, as well as information consulting services (excluding licensed information consulting services) [1] Group 2 - Junshi Biosciences holds 100% ownership of the new subsidiary [1]

聚焦珠海两会，对话城市发展"关键力量"。 今年是"十五五"的开局之年，如何承接"十四五"之成绩，为奔赴下一个五年开好局、起好步，尤为重 要。 新鲜出炉的2026年珠海市政府工作报告，全面回顾了"十四五"时期经济社会发展成就，明确"十五五"时 期经济社会发展目标，着眼于今年之可为，部署了推动粤港澳大湾区建设、发展新质生产力、推进教育 科技人才一体化发展等十个方面的重点工作。 这将带来怎样的新期待和新变化？南方都市报将邀请珠海各局局长、各区区长走进采访间，回望2025年 的亮点成绩，解读珠海2026年的新局势，展望"十五五"时期的预期目标和实现路径。 2月10日，珠海市第十届人民代表大会第六次会议开幕。11日上午8时，在珠海市十届人大六次会议"局 长通道"上，珠海市科技创新局局长黄南荫亮相并表示，2025年，珠海全社会研发投入强度4.57%、排 名全省第二；高新技术企业贡献全市规模以上工业增加值的72%；科技创新发展指数连续六年排名全国 地级市第二，"澳门—珠海"创新集群连续两年入选全球创新百强。 "2026年，我们将聚焦'服务新定位、解答新课题、增创新优势、实现新突破'的工作主线，围绕全面提 升城市能级量级，持 ...

Core Viewpoint - BaiOScitech-B (02315.HK) experienced a significant increase in stock price, rising over 6% in the afternoon trading session on February 11, reaching a price of 52.95 HKD with a trading volume of 34.03 million HKD [1] Summary by Category - **Stock Performance** - The stock price of BaiOScitech-B rose by 6.33% to 52.95 HKD [1] - The trading volume was reported at 34.03 million HKD [1]

Core Viewpoint - Baosai Tu-B (02315) has shown a significant increase in stock price, rising over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Group 1: Financial Performance - The company forecasts a revenue of approximately 1.369 billion to 1.389 billion yuan for 2025, representing a year-on-year growth of 39.61% to 41.65% [1] - Expected net profit attributable to shareholders is projected to be between 162 million to 182 million yuan, reflecting a substantial year-on-year increase of 384.26% to 443.88% [1] Group 2: Business Drivers - Guolian Minsheng Securities highlights the company's innovative advantages in model animals and preclinical CRO business, as well as the strengths of its antibody platform supported by the "Thousand Mice, Ten Thousand Antibodies" initiative [1] - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, and multiple pipelines have received IND approvals, which are expected to contribute to milestone payments and further revenue growth [1]

Core Viewpoint - Baosai Technology-B (02315) has shown a significant increase in stock price, rising over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Financial Performance - The company expects to achieve revenue of approximately 1.369 billion to 1.389 billion yuan for the year 2025, representing a year-on-year growth of 39.61% to 41.65% [1] - The anticipated net profit attributable to shareholders is projected to be around 162 million to 182 million yuan, reflecting a substantial year-on-year increase of 384.26% to 443.88% [1] Market Position and Growth Drivers - Guolian Minsheng Securities highlighted that Baosai Technology benefits from its innovative advantages in model animals and preclinical CRO business, as well as the antibody platform supported by the "Thousand Mice and Ten Thousand Antibodies" initiative [1] - The company has established partnerships with several leading domestic and international pharmaceutical companies since 2025, and multiple pipelines have received IND approvals, which are expected to contribute to milestone payments and further revenue growth [1]

以下文章来源于东四十条资本 ，作者鲁智高 东四十条资本 . 聚焦股权投资行业人物、事件、数据、研究、政策解读，提供专业视角和深度洞见 | 创投圈有趣的灵魂 将投中网设为"星标⭐"，第一时间收获最新推送 女性创业者正排队冲向IPO。 作者丨 鲁智高 编辑丨 王庆武 来源丨 东四十条资本 一家成都明星公司冲向港股。 在61岁女将陈俐娟的带领下，获得启明创投、高榕创投、五源资本、腾讯、蓝驰创投、成都科创投、川创投、策源资本、贵州百灵、上海科创基金、淡 明资本集团旗下基金等青睐的赜灵生物，于近日来到港交所门前。 沿着她前进的方向望去，更多的女性创业者正排队冲向IPO。 包括赜灵生物在内，短短一个月左右的时间，由她们打造的钱大妈、亦诺微医药、文石信息、迦智科技、爱芯元智等明星公司，也纷纷踏上IPO之路， 让人们深切感受到"她力量"。 她带队，成都诞生一家明星公司 赜灵生物的诞生，源于四川大学华西医院的科技成果转化。 时间回到2018年，在国家卫健委要求下，四川大学华西医院作为试点单位，承担起了"科技成果转移转化激励院内政策体系"的探索任务，并出台了新 的成果转化系列激励政策，从而为赜灵生物的成立埋下伏笔。 那个时候，在 ...

Group 1 - Garden Biologics' stock increased by 5.06%, reaching 18.68 CNY per share, with a trading volume of 356 million CNY and a turnover rate of 3.65%, resulting in a total market capitalization of 10.152 billion CNY [1] - The company, Zhejiang Garden Biologics Co., Ltd., was established on December 18, 2000, and went public on October 9, 2014. Its main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition of the company includes vitamin products at 47.41%, pharmaceuticals at 30.22%, lanolin and its derivatives at 20.93%, sales of raw materials and others at 1.01%, rental income at 0.31%, other trade products at 0.10%, and medical devices at 0.01% [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Garden Biologics, having reduced its holdings by 48,400 shares to 3.4785 million shares, representing 0.65% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 78.996 billion CNY. Year-to-date returns are 8.61%, ranking 1564 out of 5569 in its category, while the one-year return is 34.61%, ranking 1862 out of 4295 [2] Group 3 - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 98 days. The total asset scale under management is 137.02 billion CNY, with the best fund return during the tenure being 251.88% and the worst being -15.93% [3]

Core Viewpoint - The collaboration between Zhuhai and Hong Kong in technology innovation and industrial linkage is a focal point of discussion during the "Two Sessions" in Zhuhai, aiming to create new advantages for the development of the Guangdong-Hong Kong-Macao Greater Bay Area [1] Group 1: Advantages of Zhuhai - Zhuhai is strategically located at the intersection of three major metropolitan areas, making it the first stop for technology resources connecting to Hong Kong [2] - The city has a gradually improving industrial ecosystem in integrated circuits, biomedicine, and marine economy [2] - Lower land and labor costs compared to Shenzhen and Hong Kong make Zhuhai suitable for project trials and large-scale production [2] - Innovative policies such as "Hong Kong vehicles entering the mainland" and "Zhuhai-Hong Kong talent card" facilitate cross-border collaboration [2] Group 2: Advantages of Hong Kong - Hong Kong boasts a concentration of world-class universities and research institutions, providing rich innovation resources [3] - The city has diverse financing channels and international financial service capabilities [3] - Institutional advantages such as cross-border use of research funds and expedited customs for experimental equipment enhance cross-border scientific collaboration [3] Group 3: Recommendations for Collaboration - Establish a regular collaboration mechanism by setting up a Zhuhai-Hong Kong industrial linkage task force to hold joint meetings and approve major cooperation projects [4] - Support Hong Kong enterprises in utilizing Zhuhai's land and facilities for R&D centers, pilot bases, and manufacturing parks to overcome spatial limitations [5] - Enhance cross-border trade convenience by deepening the effects of "Hong Kong vehicles entering the mainland" and exploring integrated cross-border supply chain supervision [6] - Facilitate the flow of innovative elements by encouraging joint laboratories between institutions and enterprises from both regions [7] - Co-build a regional innovation community by collaborating with Hong Kong to establish the Zhuhai-Western Science City and promote the integration of industry, technology, and scenarios [8] - Improve personnel exchanges and transportation by implementing a "one visa for multiple entries" policy for travel from Zhuhai to Hong Kong and accelerating the construction of maritime routes [9]

Core Insights - The article emphasizes the importance of cross-regional collaboration in various industries, particularly in sectors like new energy vehicles, biomedicine, and artificial intelligence, through initiatives like the "dual empowerment" industry matchmaking event in Guangzhou [2][5]. Group 1: Event Overview - The "dual empowerment" industry matchmaking event in Guangzhou featured over 20 high-quality enterprises from sectors such as new energy vehicles, biomedicine, and artificial intelligence, promoting their products, technologies, and collaboration opportunities [2]. - The event aims to establish a clear pathway for precise collaboration, transitioning from "list matching" to "ecological co-construction" [5]. Group 2: Collaboration Mechanisms - Guangzhou is implementing a dynamic mechanism for continuous updating and precise matching of collaboration projects, resulting in 23 key cooperation projects identified to date [5]. - The city plans to host 17 specialized matchmaking events in 13 domestic cooperation cities by 2025, attracting over 450 enterprises and institutions to facilitate efficient resource flow and collaboration [5]. Group 3: Industry Synergy and Benefits - The collaboration efforts are designed to enhance the high-end industrial landscape, focusing on sectors like new energy vehicle sales, low-altitude economy, digital technology, and biomedicine, leading to successful project implementations [6]. - The initiative not only extends Guangzhou's advantageous industries but also aids partner regions in industry transfer and the cultivation of new productive forces [7]. Group 4: Economic Impact - Since 2025, Guangzhou has completed or signed over 80 cooperation projects, with a total economic cooperation amount exceeding 10 billion yuan, showcasing the value of cross-regional collaboration [8]. - The city has organized 17 promotional matchmaking activities, attracting 245 Guangzhou enterprises and achieving a trade cooperation scale surpassing 7 billion yuan [8].